3 results match your criteria: "University Hospital of Dijon and University of Burgundy[Affiliation]"
Positive Predictive Value of French Hospitalization Discharge Codes for Stroke and Transient Ischemic Attack.
Eur Neurol
January 2018
Dijon Stroke Registry (INSERM, INVS, EA 4184), University Hospital of Dijon and University of Burgundy, Dijon, France.
Background: We aimed at measuring the positive predictive value (PPV) of data in the French Hospital Medical Information Database (FHD).
Summary: This retrospective multicenter study included 31 hospitals from where 56 hospital stays were randomly selected among all hospitalizations for the years 2009 and 2010 with at least 1 principal diagnosis of stroke or transient ischemic attack (TIA). Three algorithms were evaluated.
Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.
Cancer Epidemiol Biomarkers Prev
July 2015
Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, United Kingdom.
Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported.
Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988-2008) were pooled.
Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
J Natl Cancer Inst Monogr
August 2014
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA (PMB, EAH); Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d'Oncologia, IDIBELL, Barcelona, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain (YB, SdS); Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, Australia, The Australian School of Advanced Medicine, Macquarie University, Sydney, Australia (JJT); Department of Entomology, The Robert H. Smith Faculty of Agriculture, Koret School of Veterinary Medicine Veterinary Teaching Hospital, Hebrew University of Jerusalem, Rehovot, Israel (OP); Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN (SLS, ADN, JRC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany (NB); Department of Health Studies, University of Chicago, Chicago, IL (BCHC); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD); Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany (AN); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (EVK, ER); Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (KES); Biological Hematology Unit, CRB Ferdinand Cabanne, University Hospital of Dijon and University of Burgundy, Dijon, France (MM); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada (JJS); Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden, Department of Oncology and Pathology, Karolinska Institutet, Stockhol
Background: Marginal zone lymphoma (MZL), comprised of nodal, extranodal, and splenic subtypes, accounts for 5%-10% of non-Hodgkin lymphoma cases. A detailed evaluation of the independent effects of risk factors for MZL and its subtypes has not been conducted.
Methods: Data were pooled from 1052 MZL cases (extranodal [EMZL] = 633, nodal [NMZL] = 157, splenic [SMZL] = 140) and 13766 controls from 12 case-control studies.